Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + carboplatin + Endostar
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + carboplatin + Endostar is a three-drug combination regimen used primarily in the treatment of advanced non-small cell lung cancer (NSCLC). Gemcitabine and carboplatin are cytotoxic chemotherapeutic agents that inhibit DNA synthesis and induce apoptosis in rapidly dividing cells. Gemcitabine is an antimetabolite, while carboplatin is a platinum-based alkylating agent. Endostar, also known as recombinant human endostatin or rh-endostatin, is an antiangiogenic biologic that inhibits tumor angiogenesis by blocking vascular endothelial growth factor (VEGF) pathways and suppressing endothelial cell proliferation. The combination aims to enhance antitumor efficacy by targeting both tumor cells directly and their supporting vasculature. Clinical studies have shown improved disease control rates and progression-free survival with this regimen compared to chemotherapy alone, particularly in NSCLC patients[2][3].
- Brand names
- Gemzar (gemcitabine)Paraplatin (carboplatin)
- Other names
- recombinant human endostatin (for Endostar)rh-endostatin (for Endostar)
02
Targets
NCL (Nucleolin)DNA polymerase familyRNR (Ribonucleotide reductase)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA
Beyond the preview
Go deeper on gemcitabine + carboplatin + Endostar.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + carboplatin + Endostar.